Company
Portfolio Data
Amplified Sciences, LLC
UEI: RCKST9F41YA6
Number of Employees: 4
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
SBIR/STTR Involvement
Year of first award: 2023
2
Phase I Awards
0
Phase II Awards
N/A
Conversion Rate
$729,635
Phase I Dollars
$0
Phase II Dollars
$729,635
Total Awarded
Awards
SBIR Phase I: Development of a SERS-based diagnostic platform for multiplexing ubiquitous inflammatory markers in cancer.
Amount: $274,750 Topic: BM
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project stems from the fact that cancer causes approximately 10 million deaths yearly worldwide, and the economic burden on cancer patients in the United States alone is estimated to be around $21 billion/yr, excluding lost productivity. Over 600,000 people die from cancer in the United States each year, and cancer cases among the younger population are on the rise. Currently, only a handful of cancers, such as breast, colon, cervical, and prostate, have recommended early screening, and sadly, 70% of cancer deaths are caused by cancers without recommended screening. Early detection, coupled with accurate monitoring and surgery in appropriate cases, appears to be the ideal strategy to improve outcomes and quality of life and reduce healthcare costs. The availability of novel diagnostic technology for minimally invasive biomarker analysis using biofluids to accurately predict malignancy potential would greatly benefit patients and clinicians in the early diagnosis and management of deadly cancers. Development of the technology proposed herein would have a broad impact on the cancer diagnostic space in terms of accurate early detection and diagnosis, quality of life, mortality, and healthcare burden. This Small Business Innovation Research (SBIR) Phase I project aims to develop multi-marker diagnostic assays to bridge a critical gap from biomarker discovery to diagnostic assay translation. This project leverages principles from synthetic chemistry, enzymology, spectroscopy, and engineering, leading to a novel biosensing platform that couples Surface-Enhanced Raman Spectroscopy (SERS) and a protease turnover assay to provide highly accurate methods for biomarker detection. This project will lead to developing next-generation sensors to meet the unique requirements for a multi-molecular protease activity assay from highly viscous, proteinaceous clinical samples and deliver a stackable assay workflow readily accessible to clinical laboratory staff with rapid turnaround. The technological hurdles that will be addressed during Phase I will include: 1) synthetic development of ultrasensitive SERS-active dyes and their conjugates with substrates of proteases associated with high-grade dysplasia in pancreatic cysts and other cancers, and 2) development and optimization of a multiplexed multi-protease turnover assay employing the aforementioned substrates using an automated-SERS detection platform with high-throughput capability for eventual commercialization in a CLIA lab setting. This technology has the potential to be transformative due to its multiplexing capability, high sensitivity and selectivity, cost-effectiveness, and reliable performance in complex biological fluids. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Tagged as:
SBIR
Phase I
2024
NSF
Translating a Novel Assay for Risk Stratification of Potentially Malignant Pancreatic Cystic Lesions
Amount: $454,885 Topic: 102
1. Executive Summary Pancreatic cancer has a depressing 5-year survival rate estimated at 12%. The dismal outlook is due to myriad issues, including the fact that patients are asymptomatic in early stages combined with the lack of screening tools. One window to earlier detection is through pancreatic cystic lesions detected incidentally in routine imaging analyses for diagnosis of unrelated disorders. These patients are at an increased risk for pancreatic cancer. Unfortunately, imaging is insufficient for distinguishing benign cysts from those likely to progress to cancer forcing clinicians to rely on biochemical analyses of acellular cyst fluid. The current assays display poor accuracy and require large volumes of fluid not always available limiting their clinical utility. There is a profound unmet clinical need for diagnostics that accurately grade dysplasia in mucinous pancreatic cyst fluids. The objective of current SBIR Phase I grant (CA277913-01A1 effective May 2023) is to develop and conduct clinical translation of a diagnostic assay panel using ultrasensitive detection methods to grade dysplasia in pancreatic cysts. This assay will stratify patients most at risk for progression to cancer thus providing high clinical utility. The platform: Amplified Sciences has utilized a proprietary platform to translate to the company roscopy platform is robust and readily adaptable to other proteolytic enzymes as needed for this grant. To date, the company has made strong progress on the Aims. The team has built a new direct-detection SERS ligand binding platform (prototype stage) for two of the biomarkers, and adapted the existing enzymatic activity assay for a third. Over 90 retrospective clinical samples have been procured, and all clinical testing and statistical analysis should be complete by end of Phase 1. The company is on track -ready assay protocol for full clinical validation and algorithm development in a Phase 2 grant. Several challenges have been met and overcome. Technical challenges including delays in the supply chain have been overcome by securing new suppliers for chemicals, etc. Administrative challenges include delays from securing invoices from vendors, so more frequent reminders have been implemented. Finally, commercial challenges include limited funding for market research with doctors and payers to gain the insights needed to prepare for commercial launch and challenges in accessing clinicians at large academic centers. To overcome this, the company has leveraged current clinical investigators for introductions. Finally, the current capital market for fundraising is very challenging so the company has supplemented investor funds with non-dilutive funding totaling $1M of research use only revenue and state and federal grants. Specific Aims: Aim 1: Validate a combination of three (3) protease activity markers to accurately distinguish low- grade from high-grade mucinous pancreatic cystic neoplasms. Aim 2: To develop quantitative assays for a panel of three (3) markers in low-volume mock cyst fluid samples that enable diagnostic power evaluation in a clinical sample cohort. Below employees are committed to I-Corps requirements: Diana Caldwell, CEO and Co-founder (C- er) Daniel Sheik, PhD, Director of Research and Technology John R. Ridge, Commercial and Market Access Director (Industry Expert)
Tagged as:
SBIR
Phase I
2023
HHS
NIH